Compare · ICAD vs MDLN
ICAD vs MDLN
Side-by-side comparison of iCAD Inc. (ICAD) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICAD and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.28B, about 335.2x ICAD ($135.1M).
- Over the past year, ICAD is up 2.7% and MDLN is down 14.9% - ICAD leads by 17.5 points.
- MDLN has hit the wire 21 times in the past 4 weeks while ICAD has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 5 for ICAD).
- Company
- iCAD Inc.
- Medline Inc.
- Price
- $3.87+2.79%
- $34.71+0.71%
- Market cap
- $135.1M
- $45.28B
- 1M return
- +5.16%
- -23.52%
- 1Y return
- +2.65%
- -14.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 21
- Recent ratings
- 5
- 25
iCAD Inc.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Latest ICAD
- MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
- SEC Form 15-12G filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)